Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: A multicenter study

Cancer

Volumn 118, Issue 15, 2012, Pages 3812-3821

  Dufour, Christelle ^a   Beaugrand, Annick ^a   Le Deley, Marie Cécile ^a,b   Bourdeaut, Franck ^c   André, Nicolas ^d   Leblond, Pierre ^e   Bertozzi, Anne Isabelle ^f   Frappaz, Didier ^g   Rialland, Xavier ^h   Fouyssac, Fanny ⁱ   Edan, Christine ^j   Grill, Jacques ^a   Quidot, Marion ^a   Varlet, Pascale ^k  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT CURIE   (France)

^d TIMONE HOSPITAL   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g CENTRE LÉON BÉRARD   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k CENTRE HOSPITALIER SAINTE ANNE   (France)

more..

Author keywords

atypical teratoid rhabdoid tumors; claudin 6; clinical and pathologic features; pediatric oncology; prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CARBOPLATIN; CISPLATIN; CLAUDIN 6; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; KI 67 ANTIGEN; MELPHALAN; NUCLEAR PROTEIN; PROCARBAZINE; PROTEIN INI1; PROTEIN P53; THIOTEPA; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; ATYPICAL TERATOID TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL NUCLEUS; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FRANCE; GENE; GENE MUTATION; HISTOPATHOLOGY; HSNF5 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; INI1 GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RHABDOID TUMOR; SMARCB1 GENE; SURVIVAL TIME; TERATOMA;

BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROGNOSIS; RHABDOID TUMOR; RISK FACTORS; TERATOMA;

EID: 84864118142     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26684     Document Type: Article

References (26)

1. Oka H, Scheithauer BW,. Clinicopathological characteristics of atypical teratoid/rhabdoid tumor. Neurol Med Chir. 1999; 39: 510-517.
2. Olson TA, Bayar E, Kosnik E, et al. Successful treatment of disseminated central nervous system malignant rhabdoid tumor. J Pediatr Hematol Oncol. 1995; 17: 71-75.
3. Rorke LB, Packer RJ, Biegel JA,. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996; 85: 56-65.
4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
5. Biegel JA, Rorke LB, Packer RJ, Emanuel BS,. Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg. 1990; 73: 710-714.
6. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B,. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999; 59: 74-79.
7. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998; 394: 203-206.
8. Bourdeaut F, Freneaux P, Thuille B, et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol. 2007; 211: 323-330.
9. Schneppenheim R, Fruhwald MC, Gesk S, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet. 2010; 86: 279-284.
10. Birks DK, Kleinschmidt-Demasters BK, Donson AM, et al. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2009; 20: 140-150.
11. Loda M, Xu X, Pession A, Vortmeyer A, Giangaspero F,. Membranous expression of glucose transporter-1 protein (GLUT-1) in embryonal neoplasms of the central nervous system. Neuropathol Appl Neurobiol. 2000; 26: 91-97.
12. Varlet P, Beaugrand A, Lacroix L, et al. Atypical teratoid rhabdoid tumor mimicking beta-catenin-positive nodular medulloblastoma. Acta Neuropathol. 2011; 121: 429-430.
13. Chang CH, Housepian EM, Herbert C Jr,. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas. Radiology. 1969; 93: 1351-1359.
14. Dufour C, Grill J, Lellouch-Tubiana A, et al. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer. 2006; 42: 2939-2945.
15. Dufour C,. Sequential high-dose chemotherapy and reduced craniospinal irradiation in young children with metastatic medulloblastoma [abstract]. Neuro-Oncology. 2008; 10: 423.
16. Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004; 22: 2877-2884.
17. Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005; 23: 1491-1499.
18. Kordes U, Gesk S, Fruhwald MC, et al. Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer. 2010; 49: 176-181.
19. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009; 27: 385-389.
20. Reinhard H, Reinert J, Beier R, et al. Rhabdoid tumors in children: prognostic factors in 70 patients diagnosed in Germany. Oncol Rep. 2008; 19: 819-823.
21. Antonelli M, Hasselblatt M, Haberler C, et al. Claudin-6 is of limited sensitivity and specificity for the diagnosis of atypical teratoid/rhabdoid tumors. Brain Pathol. 2011; 21: 558-563.
22. Athale UH, Duckworth J, Odame I, Barr R,. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol. 2009; 31: 651-663.
23. Gardner SL, Asgharzadeh S, Green A, Horn B, McCowage G, Finlay J,. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer. 2008; 51: 235-240.
24. Meyers SP, Khademian ZP, Biegel JA, Chuang SH, Korones DN, Zimmerman RA,. Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes. Am J Neuroradiol. 2006; 27: 962-971.
25. Zimmerman MA, Goumnerova LC, Proctor M, et al. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol. 2005; 72: 77-84.
26. Fidani P, De Ioris MA, Serra A, et al. A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience. J Neurooncol. 2009; 92: 177-183.